PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

医学 恩扎鲁胺 前列腺癌 内科学 危险系数 安慰剂 临床终点 雄激素剥夺疗法 多西紫杉醇 醋酸阿比特龙酯 肿瘤科 无进展生存期 奥拉帕尼 中期分析 置信区间 随机对照试验 雄激素受体 癌症 化疗 病理 聚ADP核糖聚合酶 化学 替代医学 基因 聚合酶 生物化学
作者
Fred Saad,Andrew J. Armstrong,Antoine Thiery-Vuillemin,Mototsugu Oya,Eugenia Loredo,Giuseppe Procopio,J. Menezes,Gustavo Girotto,Cagatay Arslan,Niven Mehra,Francis Parnis,Emma Brown,Friederike Schlürmann,Jae Young Joung,Mikio Sugimoto,Christian Poehlein,Elizabeth A. Harrington,Chintu Desai,Jinyu Kang,Noel W. Clarke
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (6_suppl): 11-11 被引量:41
标识
DOI:10.1200/jco.2022.40.6_suppl.011
摘要

11 Background: Preclinical studies have shown combined anti-tumor effect through interactions between poly(adenosine diphosphate–ribose) polymerase and androgen receptor signaling pathways. A Phase II trial (NCT01972217) in pts with mCRPC unselected by homologous recombination repair (HRR) status who previously received docetaxel demonstrated improved radiographic progression-free survival (rPFS) for pts treated with ola + abi vs pbo + abi (Clarke N, 2018). The Phase III PROpel study (NCT03732820) evaluates the efficacy and safety of ola + abi in the 1L mCRPC setting. Methods: PROpel is a randomized, double-blind, placebo-controlled Phase III trial in pts with mCRPC undergoing 1L treatment after failure of primary androgen deprivation therapy, enrolled independent of HRR status. Pts were randomized 1:1 to receive ola (300 mg twice daily [bid]) or pbo, and abi (1000 mg once daily) + prednisone or prednisolone (5 mg bid). The primary endpoint was investigator-assessed rPFS with multiple secondary endpoints, including overall survival (OS). Results:796 pts were randomized to ola + abi (n=399) or pbo + abi (n=397).In this planned interim analysis, 1L treatment with ola + abi significantly prolonged rPFS vs pbo + abi in pts with mCRPC irrespective of HRR status (24.8 vs 16.6 months; hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54–0.81; P <0.0001). Predefined subgroup analyses showed rPFS improvement across all subgroups, including pts with (HR 0.54, 95% CI 0.36–0.79) and without (HR 0.76, 95% CI 0.59–0.97) HRR mutations detected by circulating tumor DNA testing. A sensitivity analysis of rPFS by blinded independent central review was consistent with the primary analysis (HR 0.61, 95% CI 0.49–0.74; P=0.004). OS is currently immature with 228 deaths (28.6%). A trend in OS favoring ola + abi was observed (HR 0.86, 95% CI 0.66–1.12). Secondary endpoints of time to first subsequent treatment (HR 0.74, 95% CI 0.61–0.90) and time to second progression-free survival or death (HR 0.69, 95% CI 0.51–0.94) were supportive of long-term benefits. The most common grade ≥3 adverse event (AE) reported was anemia (15.1 vs 3.3%) for ola + abi vs pbo + abi; 13.8 vs 7.8% pts, respectively, discontinued ola/pbo because of an AE. The rate of AEs leading to abi discontinuation were similar in both arms (8.5 vs 8.8%). Conclusions: At interim analysis, PROpel met its primary objective, demonstrating significant improvement in rPFS for ola + abi vs pbo + abi in pts with newly detected mCRPC who had not received prior 1L therapy, irrespective of HRR status. The safety and tolerability profile of ola + abi was consistent with the known safety profiles of the individual drugs. These results demonstrate the benefit of ola + abi without the need for HRR stratification in 1L treatment of mCRPC. Pt follow-up is ongoing for the planned OS analysis. Clinical trial information: NCT03732820.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷酷亦寒完成签到 ,获得积分10
1秒前
量子星尘发布了新的文献求助10
3秒前
Blaseaka完成签到 ,获得积分10
4秒前
Owen应助科研通管家采纳,获得10
4秒前
深情安青应助科研通管家采纳,获得10
4秒前
4秒前
汉堡包应助科研通管家采纳,获得10
5秒前
小二郎应助科研通管家采纳,获得30
5秒前
爆米花应助科研通管家采纳,获得10
5秒前
沉静的浩然完成签到,获得积分10
6秒前
开朗的绮山完成签到,获得积分10
6秒前
6秒前
老迟到的土豆完成签到 ,获得积分10
9秒前
单薄的日记本完成签到,获得积分10
9秒前
大橙子发布了新的文献求助10
10秒前
舒适的天奇完成签到 ,获得积分10
11秒前
12秒前
14秒前
都是小儿卡通书完成签到,获得积分10
15秒前
16秒前
陶醉的又夏完成签到 ,获得积分10
16秒前
lily完成签到 ,获得积分10
19秒前
20秒前
子苓完成签到 ,获得积分10
22秒前
Jun完成签到 ,获得积分10
22秒前
phil完成签到,获得积分10
23秒前
祁乐安发布了新的文献求助20
23秒前
如初完成签到,获得积分10
24秒前
zzuwxj完成签到,获得积分10
27秒前
糊涂的语兰完成签到,获得积分10
31秒前
多余完成签到,获得积分10
32秒前
喝酸奶不舔盖完成签到 ,获得积分10
32秒前
朴实初夏完成签到 ,获得积分10
33秒前
33秒前
华仔应助查查make采纳,获得10
38秒前
乐乐应助普鲁卡因采纳,获得10
38秒前
美海与鱼完成签到,获得积分10
38秒前
哦豁完成签到 ,获得积分10
39秒前
阿钱小钱完成签到 ,获得积分10
40秒前
世上僅有的榮光之路完成签到,获得积分0
40秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038157
求助须知:如何正确求助?哪些是违规求助? 3575869
关于积分的说明 11373842
捐赠科研通 3305650
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022